CRS
NEUTRALMorphic Medical Appoints New CFO
The medical device company has appointed a new Chief Financial Officer with extensive experience in the industry.
Crystal Amber
153.00GBX
0.00%
Market Cap
96.75M
Volume
321
0% of avg
P/E Ratio
NaN
EPS (TTM)
N/A
Beta
N/A
Day Range
0.00p - 0.00p
52 Week Range
0.00p153.00p159.00p
153.00p
Upcoming Events
H2 2027
Estimated FDA approval for Morphic Medical Inc. RESET® device in the US
High Impact Event
CRS
NEUTRALMorphic Medical's RESET obesity treatment achieves UK regulatory approval
The medical device company has received regulatory approval to sell its innovative obesity and diabetes treatment in the UK market.
CRS
NEUTRALMorphic Medical Appoints New CEO
The medical device company has appointed a new Chief Executive with experience in the bariatric endoscopy space.
CRS
NEUTRALCrystal Amber Fund Announces Share Buyback Programme
The investment fund announces a share buyback programme to repurchase up to £2.5 million of its own shares.
CRS
NEUTRALCrystal Amber Fund Limited Announces Holding Change
The major shareholder of this investment fund has increased its stake, but no further details are provided.
CRS
NEUTRALCrystal Amber Fund Announces Director Share Sale
The investment manager of the Crystal Amber Fund has sold a portion of its shareholding in the company.
CRS
NEUTRALCrystal Amber Fund provides update on investments
The investment fund provides an update on its portfolio, including the completion of a takeover and progress with a key medical device investment.
CRS
NEUTRALCrystal Amber Fund Announces Change in Shareholding
The investment fund discloses a change in its shareholding in the company.
CRS
NEUTRALCrystal Amber Fund Announces Change in Shareholding
The investment fund discloses a change in its shareholding in the company.
CRS
GOODMorphic Medical Inc receives European regulatory approval for obesity and diabetes treatment
The medical device company has received European regulatory approval for its non-surgical obesity and diabetes treatment, paving the way for expansion across the EU.